Another SGLT-2 Inhibitor Shows Promise for Heart Failure

The DELIVER trial found benefit with dapagliflozin in patients with preserved ejection fraction.

Sodium–glucose cotransporter-2 (SGLT-2) inhibitors, initially developed to treat diabetes, have transformed drug treatment for heart failure (HF), producing substantial benefits in people with HF with or without diabetes and across the spectrum of left ventricular systolic function. The landmark EMPEROR-Preserved trial) demonstrated benefits of an SGLT-2 inhibitor (empagliflozin) in a population with HF and preserved ejection fraction (HFpEF), though these benefits were potentially lesser in the subgroup with left ventricular ejection fraction (LVEF) >60% (NEJM JW Cardiol Oct 2021).

A new manufacturer-sponsored randomized trial (DELIVER) studied the effects of dapagliflozin (10 mg/day) compared with placebo in 6263 patients (mean age, 72; 44…

Reviewing Author

Frederick A. Masoudi, MD, MSPH, MACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)